Complication, PostoperativePhase 4STEREONCT03403517
Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period
A Phase 4 study testing Methylprednisolone and Dexamethasone in people with Complication, Postoperative, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
Trial summary
Background: Several randomized clinical trials have shown beneficial effects of pre-operative glucocorticoids on post-operative complications. Studies on the effects of glucocorticoids on the postoperative recovery after liver-resection show significantly lower markers of infection and liver damage, and some studies… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Complication, Postoperative
- What is being tested?
- Methylprednisolone and Dexamethasone
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 174 participants
- Where
- 1 siteDenmark
- Study dates
- 11 Dec 2017to 28 Sep 2020
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age minimum 18
- Planned open liver resection (with or without combined ablation and/or
- cholecystectomy)
- Able to participate (self report pain/nausea)
- Understands danish/english, or has an interpreter during admission
- Signed consent form
Who cannot join
- ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy) procedure
- Combined ventral herniotomy with implantation of mesh
- Combined with operation on tumor in other organs
- Insulin dependent diabetes
- Current (<10 days) treatment with systemic glucocorticoids and/or immunosuppressive treatment (not including inhalations)
- Epidural anesthesia not feasible
Show all 9Show fewer
- Pregnancy/breastfeeding
- Allergy toward study medication
- Inoperability
Trial locations and contacts
1 site in 1 country.
About this study
Official title: High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial
Background:
Several randomized clinical trials have shown beneficial effects of pre-operative glucocorticoids on post-operative complications.
Read more
Studies on the effects of glucocorticoids on the postoperative recovery after liver-resection show significantly lower markers of infection and liver damage, and some studies have shown a shorter hospital stay.
Studies on the effects in the immediate postoperative phase are lacking.
Methods: Randomized, double-blind, controlled trial evaluating incidence of postoperative complications in the immediate postoperative phase (and during admission) after open liver surgery. Participants are randomized to either active treatment (methylprednisolone 10 mg/kg) or control (8 mg dexamethasone), administered just prior to surgery.
All patients undergoing open liver resection at our institution are eligible. Included patients are stratified according to extent of surgery into minor (<3 segments) or major (≥3 segments) group.
Patients in major group participate in Substudy I (markers of endothelial damage).
Patients operated between January and July 2018 participate in Substudy II (delirium).
Read the detailed description
Post-surgery, patients are traditionally observed and treated in post-anesthesia care units (PACU) until they are discharged to the ward (or directly home) assessed by standardized international discharge criteria.
The research project "Why in PACU?" (Rigshospitalet, Denmark), has since the beginning of 2016 systematically collected and analyzed procedure-related complications in the recovery phase. The complications include pain, nausea/vomiting, circulatory and respiratory problems, orthostatic intolerance and cognitive disorders. Common to all the above-mentioned post-operative problems are the possible links to the inflammatory response caused by the surgical trauma.
Glucocorticoids (GC) can in this context be central for the reduction of acute postoperative organ dysfunctions, caused by the anti-inflammatory effect. In a number of different surgical procedures, single dose, pre-operative glucocorticoids have been shown to reduce post-operative nausea and vomiting (PONV), acute pain and need of opioids as well as accelerate the convalescence. Meta-analyses also showed that single-dose administration of glucocorticoids (methylprednisolone and dexamethasone) for surgical patients is safe as opposed to long-term treatment.
Studies on pre-operative glucocorticoids before liver surgery have shown beneficial effects in regards to markers of liver damage and infection, but studies on clinical outcomes in the immediate post-operative phase are lacking.
The primary aim of this study is to investigate whether high dose pre-operative glucocorticoids reduce complications in the immediate post-operative course.
The investigators will also perform two hypothesis-generating sub studies:
- Sub study I - markers of endothelial dysfunction
The endothelial lining of blood vessels contributes to maintaining haemostasis, and damage can increase risks of cardiovascular and thromboembolic complications. In a recent randomized trial, pre-operative high dose glucocorticoids diminished circulating markers of endothelial damage (after knee arthroplasty). In this study we will investigate whether this also applies liver surgery, and if so, if there is any connection to cardiovascular and thromboembolic complications.
- Sub study II - delirium Studies on delirium after liver surgery show an incidence around 20%. It has not been investigated whether pre-operative glucocorticoids have an effect on this incidence.
The investigators will investigate the incidence of emergence delirium and delirium during the first postoperative day s after liver surgery.
Sample size:
The "Why in PACU?" database shows that complications requiring treatment in PACU occur in up to 40 % of patients after liver surgery. These complications are primarily respiratory and circulatory.
A 50 % reduction in the number of patients with complications requiring treatment is regarded clinically relevant. This will require a sample size of 174 patients, including 10 % dropout (80 % power, 5% level of significans, superiority design). Patients will be stratified according to extent of surgery, into minor or major resection.
The sub studies are hypothesis-generating, and are not subject to power calculations. Sub study I will include all major resections, sub study II will include patients during the first 5 months.
Analysis: Primary end point (complications in the two groups) is compared with chi square test and described with odds ratio (95%CI). Level of significance is p=0,05 Standard statistical analysis will include normally or near-normally distributed variables reported as means and non-normally distributed variables as medians. Means will be compared using the student's t test and medians using the Mann-Whitney U test. Differences in proportions among categorical data will be assessed using Fischer's exact test. A p value < 0.05 will represent statistical significance for all comparisons.
Hypothesis: Preoperative GC administration will decrease the incidence of postoperative complications and overall hospital length of stay following liver surgery. Preoperative GC administration will decrease markers of endothelial dysfunction following major liver surgery. Preoperative GC administration will decrease incidence of delirium following liver surgery.
Data collection:
Data elements to be collected will include, but not be limited to:
- Demographics (age, gender, height, weight, tobacco and alcohol consumption, comorbidities, American Society of Anaesthesiology (ASA) score)
- Preoperative chemotherapy, preoperative use of analgesics and/or other central stimulants
- Preoperative biochemistry
- Diagnosis, procedure, surgery duration
- Blood loss, transfusions, use of drain, hepatic inflow occlusion (length of)
- Postoperative pain, nausea, sedation and vitals, every 30 minutes until transfer to ward
- Postoperative pain, nausea, mood and quality of sleep, self reported, every day until discharge or postoperative day 5 (what comes first)
- Postoperative use of analgesics and anti emetics until discharge or postoperative day 5 (what comes first)
- Complications (hepatic failure, ascites, intraabdominal collection, postoperative bleeding, bile leak, bowel obstruction, wound dehiscence, reoperations, pleural effusion, pulmonary embolus, deep venous thrombosis, infections, cardiac events, cerebral events, other causes of prolonged hospital stay)
- 3-minute Diagnostic Confusion Assessment Method (3D-CAM), postoperative day 0 (all) 1-3 (major resections)
- Endothelial markers (Syndecan-1, soluble thrombomodulin, SE-selectin, vascular endothelial growth factor (VEGF) postoperative day0-3 (major resections)
- Hospital stay, length of stay in PACU
- Mortality (30 days)
The study is not placebo-controlled since the positive effects of dexamethasone 8 mg on PONV have been shown in numerous trials, and is already being administered to all patients at the clinic. It would therefore not be ethically correct to withdraw from this practise.
- Conditions
- Complication, Postoperative
- Being tested
- Methylprednisolone, Dexamethasone
- Keywords
- steroids, glucocorticoids, liver surgery, hepatectomy
- Medical subject headings
- Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Also called solu-medrol
10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
DexamethasoneDrug
Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
| Study group | Role | What they receive |
|---|---|---|
| Methylprednisolone | Experimental | 10 mg/kg, single preoperative infusion Receives: Drug: Methylprednisolone |
| Dexamethasone | Active comparator | 8 mg dexamethasone, single preoperative infusion Receives: Drug: Dexamethasone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complications, Post-anesthesia Care Unit (PACU)
Number of patients with any complication at any time, during stay in the PACU. Complications according to DASAIMS discharge criteria (modified Aldrete criteria)
Measured: up to 24 hours
Substudy I: Markers of Endothelial Dysfunction
Amount of endothelial markers (Syndecan-1, soluble thrombomodulin, SE-Selectin, vascular endothelial growth factor (VEGF) )
Measured: post-operative days 0 to 3
Substudy II: Delirium
Number of patients with post-operative cognitive impairment, according to 3-minute diagnostic confusion assessment method (3D-CAM)
Measured: 5 days
Secondary outcomes (12)
Mortality
any cause mortality
Measured: 30 days
Total Complication Rate
any complications, 30 day morbidity
Measured: 30 days
Hospital Stay
from operation to discharge
Measured: 3 months
PACU Stay
from operation to discharge from PACU
Measured: up to 24 hours
Pain at Movement
every 60 minutes, during stay in PACU. Numeric Rating Scale (NRS 0-10)
Measured: up to 24 hours
Pain, Abdominal (Postoperative)
During admission, self reported. Numeric Rating Scale (NRS 0-10)
Measured: up to five days
Nausea
During admission, self reported. (Light, none, moderate, heavy nausea)
Measured: up to five days
Analgesic Requirements
All analgesics other than standard medication, during admission. From Medical record.
Measured: up to five days
Antiemetic Requirements
All antiemetics other than standard medication, during admission. From Medical record.
Measured: up to five days
ALAT
impact on ALAT (alanin-aminotransferase) post surgery
Measured: up to five days
Bilirubin
impact on bilirubin post surgery
Measured: up to five days
INR
impact on INR (International Normalized Ratio) post surgery
Measured: up to five days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2018
- Study start11 Dec 2017
- Primary completion28 Aug 2020
- Study completion28 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Complication, PostoperativeStudies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 174 participants (actual)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kristin Julia Steinthorsdottir, Copenhagen University Hospital, Rigshospitalet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03403517
- Sponsor's protocol ID
- DEXLEV01
- Other IDs
- 2017-002652-81, 2017
- Acronym
- STEREO
- Status last verified
- Dec 2020
- First submitted
- 5 Jan 2018
- Last updated
- 5 Jan 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Steinthorsdottir KJ, Awada HN, Schultz NA, Larsen PN, Hillingso JG, Jans O, Kehlet H, Aasvang EK. Preoperative high-dose glucocorticoids for early recovery after liver resection: randomized double-blinded trial. BJS Open. 2021 Jul 6;5(5):zrab063. doi: 10.1093/bjsopen/zrab063.
PubMed 34480563
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial
- ClinicalTrials.gov ID
- NCT03403517
- Acronym / sponsor ID
- STEREO / DEXLEV01
- Conditions
- Complication, Postoperative
- Keywords
- steroids, glucocorticoids, liver surgery, hepatectomy
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 174 participants (actual)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Study start
- 11 Dec 2017 (actual)
- Primary completion
- 28 Aug 2020 (actual)
- Study completion
- 28 Sep 2020 (actual)
- First posted
- 18 Jan 2018 (actual)
- Results
- Posted 5 Jan 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Several randomized clinical trials have shown beneficial effects of pre-operative glucocorticoids on post-operative complications.
Studies on the effects of glucocorticoids on the postoperative recovery after liver-resection show significantly lower markers of infection and liver damage, and some studies have shown a shorter hospital stay.
Studies on the effects in the immediate postoperative phase are lacking.
Methods: Randomized, double-blind, controlled trial evaluating incidence of postoperative complications in the immediate postoperative phase (and during admission) after open liver surgery. Participants are randomized to either active treatment (methylprednisolone 10 mg/kg) or control (8 mg dexamethasone), administered just prior to surgery.
All patients undergoing open liver resection at our institution are eligible. Included patients are stratified according to extent of surgery into minor (<3 segments) or major (≥3 segments) group.
Patients in major group participate in Substudy I (markers of endothelial damage).
Patients operated between January and July 2018 participate in Substudy II (delirium).
Detailed description
Post-surgery, patients are traditionally observed and treated in post-anesthesia care units (PACU) until they are discharged to the ward (or directly home) assessed by standardized international discharge criteria.
The research project "Why in PACU?" (Rigshospitalet, Denmark), has since the beginning of 2016 systematically collected and analyzed procedure-related complications in the recovery phase. The complications include pain, nausea/vomiting, circulatory and respiratory problems, orthostatic intolerance and cognitive disorders. Common to all the above-mentioned post-operative problems are the possible links to the inflammatory response caused by the surgical trauma.
Glucocorticoids (GC) can in this context be central for the reduction of acute postoperative organ dysfunctions, caused by the anti-inflammatory effect. In a number of different surgical procedures, single dose, pre-operative glucocorticoids have been shown to reduce post-operative nausea and vomiting (PONV), acute pain and need of opioids as well as accelerate the convalescence. Meta-analyses also showed that single-dose administration of glucocorticoids (methylprednisolone and dexamethasone) for surgical patients is safe as opposed to long-term treatment.
Studies on pre-operative glucocorticoids before liver surgery have shown beneficial effects in regards to markers of liver damage and infection, but studies on clinical outcomes in the immediate post-operative phase are lacking.
The primary aim of this study is to investigate whether high dose pre-operative glucocorticoids reduce complications in the immediate post-operative course.
The investigators will also perform two hypothesis-generating sub studies:
- Sub study I - markers of endothelial dysfunction
The endothelial lining of blood vessels contributes to maintaining haemostasis, and damage can increase risks of cardiovascular and thromboembolic complications. In a recent randomized trial, pre-operative high dose glucocorticoids diminished circulating markers of endothelial damage (after knee arthroplasty). In this study we will investigate whether this also applies liver surgery, and if so, if there is any connection to cardiovascular and thromboembolic complications.
- Sub study II - delirium Studies on delirium after liver surgery show an incidence around 20%. It has not been investigated whether pre-operative glucocorticoids have an effect on this incidence.
The investigators will investigate the incidence of emergence delirium and delirium during the first postoperative day s after liver surgery.
Sample size:
The "Why in PACU?" database shows that complications requiring treatment in PACU occur in up to 40 % of patients after liver surgery. These complications are primarily respiratory and circulatory.
A 50 % reduction in the number of patients with complications requiring treatment is regarded clinically relevant. This will require a sample size of 174 patients, including 10 % dropout (80 % power, 5% level of significans, superiority design). Patients will be stratified according to extent of surgery, into minor or major resection.
The sub studies are hypothesis-generating, and are not subject to power calculations. Sub study I will include all major resections, sub study II will include patients during the first 5 months.
Analysis: Primary end point (complications in the two groups) is compared with chi square test and described with odds ratio (95%CI). Level of significance is p=0,05 Standard statistical analysis will include normally or near-normally distributed variables reported as means and non-normally distributed variables as medians. Means will be compared using the student's t test and medians using the Mann-Whitney U test. Differences in proportions among categorical data will be assessed using Fischer's exact test. A p value < 0.05 will represent statistical significance for all comparisons.
Hypothesis: Preoperative GC administration will decrease the incidence of postoperative complications and overall hospital length of stay following liver surgery. Preoperative GC administration will decrease markers of endothelial dysfunction following major liver surgery. Preoperative GC administration will decrease incidence of delirium following liver surgery.
Data collection:
Data elements to be collected will include, but not be limited to:
- Demographics (age, gender, height, weight, tobacco and alcohol consumption, comorbidities, American Society of Anaesthesiology (ASA) score)
- Preoperative chemotherapy, preoperative use of analgesics and/or other central stimulants
- Preoperative biochemistry
- Diagnosis, procedure, surgery duration
- Blood loss, transfusions, use of drain, hepatic inflow occlusion (length of)
- Postoperative pain, nausea, sedation and vitals, every 30 minutes until transfer to ward
- Postoperative pain, nausea, mood and quality of sleep, self reported, every day until discharge or postoperative day 5 (what comes first)
- Postoperative use of analgesics and anti emetics until discharge or postoperative day 5 (what comes first)
- Complications (hepatic failure, ascites, intraabdominal collection, postoperative bleeding, bile leak, bowel obstruction, wound dehiscence, reoperations, pleural effusion, pulmonary embolus, deep venous thrombosis, infections, cardiac events, cerebral events, other causes of prolonged hospital stay)
- 3-minute Diagnostic Confusion Assessment Method (3D-CAM), postoperative day 0 (all) 1-3 (major resections)
- Endothelial markers (Syndecan-1, soluble thrombomodulin, SE-selectin, vascular endothelial growth factor (VEGF) postoperative day0-3 (major resections)
- Hospital stay, length of stay in PACU
- Mortality (30 days)
The study is not placebo-controlled since the positive effects of dexamethasone 8 mg on PONV have been shown in numerous trials, and is already being administered to all patients at the clinic. It would therefore not be ethically correct to withdraw from this practise.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Methylprednisolone | Experimental | Drug: Methylprednisolone10 mg/kg, single preoperative infusion |
| Dexamethasone | Active comparator | Drug: Dexamethasone8 mg dexamethasone, single preoperative infusion |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age minimum 18
- Planned open liver resection (with or without combined ablation and/or
- cholecystectomy)
- Able to participate (self report pain/nausea)
- Understands danish/english, or has an interpreter during admission
Key exclusion criteria (9 listed)
- ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy) procedure
- Combined ventral herniotomy with implantation of mesh
- Combined with operation on tumor in other organs
- Insulin dependent diabetes
- Current (<10 days) treatment with systemic glucocorticoids and/or immunosuppressive treatment (not including inhalations)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MethylprednisoloneAlso: solu-medrol10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery | Drug | Methylprednisolone |
| DexamethasoneDexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery | Drug | Dexamethasone |
Primary outcome
Complications, Post-anesthesia Care Unit (PACU)
Time frame: up to 24 hours
Number of patients with any complication at any time, during stay in the PACU. Complications according to DASAIMS discharge criteria (modified Aldrete criteria)
Substudy I: Markers of Endothelial Dysfunction
Time frame: post-operative days 0 to 3
Amount of endothelial markers (Syndecan-1, soluble thrombomodulin, SE-Selectin, vascular endothelial growth factor (VEGF) )
Substudy II: Delirium
Time frame: 5 days
Number of patients with post-operative cognitive impairment, according to 3-minute diagnostic confusion assessment method (3D-CAM)
12 secondary outcomes
Mortality
Time frame: 30 days
Total Complication Rate
Time frame: 30 days
Hospital Stay
Time frame: 3 months
PACU Stay
Time frame: up to 24 hours
Pain at Movement
Time frame: up to 24 hours
Pain, Abdominal (Postoperative)
Time frame: up to five days
Nausea
Time frame: up to five days
Analgesic Requirements
Time frame: up to five days
Antiemetic Requirements
Time frame: up to five days
ALAT
Time frame: up to five days
Bilirubin
Time frame: up to five days
INR
Time frame: up to five days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 34480563Steinthorsdottir KJ, Awada HN, Schultz NA, Larsen PN, Hillingso JG, Jans O, Kehlet H, Aasvang EK. Preoperative high-dose glucocorticoids for early recovery after liver resection: randomized double-blinded trial. BJS Open. 2021 Jul 6;5(5):zrab063. doi: 10.1093/bjsopen/zrab063.
Related trials for Complication, Postoperative
Not yet recruiting
The Effect of Compound Chamomile and Lidocaine Hydronchloride Gel as an Endotracheal Tube Lubricant on Postoperative Pharyngeal and Laryngeal Complications in Thoracic Surgery Patients
Postoperative Sore Throat
Enrolling by invitationPhase 4
Effects of Ciprofol on Perioperative Neurocognitive Function in Elderly Patients Undergoing Daytime Surgery
PND, POCD - Postoperative Cognitive Dysfunction
Not yet recruitingPhase 3
Lactium Premedication to Prevent Emergence Agitation
Lactium, Premedication
Active, not recruitingPhase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Methylprednisolone and Dexamethasone in people with Complication, Postoperative, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Jan 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complications, Post-anesthesia Care Unit (PACU) (time frame: up to 24 hours). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03403517, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2021.